Talk:Trastuzumab/hyaluronidase
Jump to navigation
Jump to search
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Trastuzumab/hyaluronidase.
|
Copyright tag
@SUSTAMI: The incriminated text is from https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-new-formulation-herceptin-subcutaneous-use, as referenced, which is in the public domain. I think it's very unlikely that the FDA copied this from ONS; it's probably the other way round. (Unfortunately there does not seem to be a publishing date on the FDA page, only "Content current as of". --ἀνυπόδητος (talk) 07:08, 9 August 2020 (UTC)
- @SUSTAMI and Diannaa: The voice.ons.org page is a copy of the FDA page. Content on the FDA web site is in the public domain. --Whywhenwhohow (talk) 07:20, 9 August 2020 (UTC)
- The FDA page appears to have been published Feb 28, 2019, and the ONS page on March 1.— Diannaa (talk) 12:59, 9 August 2020 (UTC)